The Effect of New Zealand Blackcurrant (NZBC) Supplementation on Recovery Following Strenuous Exercise (CurraNZ_MD)

University of Surrey

Status: Completed

Conditions: Muscle Damage

Treatments: Dietary Supplement: Placebo (PLA); Dietary Supplement: New Zealand blackcurrants (NZBC)

Study type: Interventional

Funder types: Other

Identifiers

NCT05010057

UEC/2015/112/FHMS

Details and patient eligibility

About

The study aims to examine the effect of a New Zealand blackcurrant (NZBC) supplement on markers of muscle damage and recovery following strenuous resistance exercise. The investigation will compare responses between an experimental (NZBC capsule, 300 mg/day) and placebo (PLA capsule, 300 mg sugar) group. Participants will attend a screening session where they will consent to the study, complete a pre-activity medical questionnaire and have their height, weight and resting blood pressure measured. If the participants meet the inclusion criteria they will perform a familarisation session on the muscle strength assessment. Participants will be randomized to NZBC or placebo groups, and consume one capsule in the morning (between 6-10 am) for 12 days. This is a double-blinded study, which means that the participant and the study team will not know which group the participants are assigned to until the study is over. On day 8 participants will perform a strenuous bout of upper body resistance exercise on the isokinetic dynamometer (exercise device). Muscle strength and soreness, arm circumference, and elbow range of motion will be measured, and a fasted blood sample will be collected, before and 24, 48, 72 & 96 hours after the muscle fatigue protocol (on days 9, 10, 11 & 12). A marker of muscle damage (creatine kinase [CK] concentration) will be measured in the blood samples. Participants will also be asked to complete a 6-day dietary record, beginning on day 7 and ending on the final day of testing (day 12).

Enrollment: 27 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and Females
• 18 - 45 years old
• BMI: 19 - 29.9 kg/m2
• Healthy: no active disease process that could interfere with endpoints measured as determined by medical history

Exclusion criteria

• Smoking and tobacco use
• Takes medication [excluding contraception]
• BMI ≥ 30 kg/m2
• Hypertensive (diastolic > 90 and/or systolic blood pressure > 140 mmHg)
• History of musculoskeletal upper limb injuries
• Performs regular resistance exercise (> 2 sessions per week)
• Uses dietary supplements that could influence muscle recovery or function (e.g. protein supplements, antioxidants etc)

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

27 participants in 2 patient groups, including a placebo group

New Zealand blackcurrants (NZBC)

Experimental group

Description:

1 NZBC capsule (containing 300 mg active cassis containing 105 mg of anthocyanins, i.e. 35-50 % delphinidin-3-rutinoside, 5-20 % delphinidin-3-glucoside, 30-45 % cyanidin-3-rutinoside, 3-10 % cyanidin-3-glucoside), consumed in the morning, for 12 days.

Treatment:

Dietary Supplement: New Zealand blackcurrants (NZBC)

Placebo (PLA)

Placebo Comparator group

Description:

1 placebo capsule (containing 300 mg microcrystalline cellulose M102), consumed in the morning, for 12 days.

Treatment:

Dietary Supplement: Placebo (PLA)